MRI-guided laser ablation of neuroendocrine tumor hepatic metastases

Acta Radiol Short Rep. 2014 Jan 23;3(1):2047981613499753. doi: 10.1177/2047981613499753. eCollection 2014 Jan.

Abstract

Background: Neuroendocrine tumors (NET) represent a therapeutically challenging and heterogeneous group of malignancies occurring throughout the body, but mainly in the gastrointestinal system.

Purpose: To describe magnetic resonance imaging (MRI)-guided laser ablation of NET liver metastases and assess its role within the current treatment options and methods.

Material and methods: Two patients with NET tumor hepatic metastases were treated with MRI-guided interstitial laser ablation (LITT). Three tumors were treated. Clinical follow-up time was 10 years.

Results: Both patients were successfully treated. There were no local recurrences at the ablation site during the follow-up. Both patients had survived at 10-year follow-up. One patient is disease-free.

Conclusion: MRI-guided laser ablation can be used to treat NET tumor liver metastases but combination therapy and a rigorous follow-up schedule are recommended.

Keywords: MRI; NET; ablation; laser; liver; metastasis; tumor.

Publication types

  • Case Reports